Current Report Filing (8-k)
February 08 2021 - 4:10PM
Edgar (US Regulatory)
0001446847
false
0001446847
2021-02-04
2021-02-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
Current Report Pursuant to
Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
February 4, 2021
IRONWOOD PHARMACEUTICALS, INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
|
001-34620
|
|
04-3404176
|
|
|
|
|
|
(State or other jurisdiction
|
|
|
|
(I.R.S. Employer
|
of incorporation)
|
|
(Commission File Number)
|
|
Identification Number)
|
100 Summer Street, Suite 2300
|
|
|
|
|
Boston, Massachusetts
|
|
|
|
02110
|
|
|
|
|
|
(Address of principal
|
|
|
|
|
executive offices)
|
|
|
|
(Zip code)
|
(617) 621-7722
(Registrant’s telephone number,
including area code)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
o
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of
the Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
Class A common stock, $0.001 par value
|
IRWD
|
Nasdaq Global Select Market
|
Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this
chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company o
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Item 5.02 Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On February 4, 2021, Mark Mallon notified
Ironwood Pharmaceuticals, Inc. (the “Company”) that he is resigning from his position as Chief Executive Officer and
a member of the Company’s Board of Directors, in each case effective March 12, 2021 (the “Transition Date”).
Upon the Transition Date, Thomas McCourt (age 63), who is the President of the Company, also will become the Company’s interim
Chief Executive Officer and will serve as the Company’s principal executive officer. Julie McHugh, who is currently the Chairperson
of the Board of Directors, will become Executive Chairperson of the Board of Directors upon the Transition Date and, in that capacity,
will provide counsel and guidance to the Company’s senior leadership team through the transition in addition to her current
responsibilities. Ms. McHugh will not become an employee of the Company in connection with her assuming the role of Executive Chairperson.
Mr. Mallon’s resignation is not due to any disagreement with the Company on any matter relating to the Company’s operations,
policies or practices.
Biographical information for Mr. McCourt
is available in the Company’s proxy statement filed with the Securities and Exchange Commission (the “SEC”) on
April 21, 2020, in connection with the Company’s 2020 annual meeting of stockholders, such information being incorporated
herein by reference. There is no arrangement or understanding between Mr. McCourt and any other person pursuant to which Mr. McCourt
was selected as the Company’s interim Chief Executive Officer or principal executive officer, effective on the Transition
Date. There is no family relationship between Mr. McCourt and any director, executive officer, or person nominated or chosen
by the Company to become a director or executive officer of the Company. Mr. McCourt is not, and has not been since January 1,
2020, a participant in any transaction involving the Company, and is not a participant in any proposed transaction with the Company,
required to be disclosed pursuant to Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended.
This Current Report on Form 8-K contains
forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements,
including statements about anticipated leadership transitions, including the expected date and duration thereof. Each
forward-looking statement is subject to risks and uncertainties that could cause actual events to differ materially from
those expressed or implied in such statement. Applicable risks and uncertainties include those related to the possibility
that the leadership transitions do not occur as anticipated for any reason or on the expected timing and the risks listed
under the heading “Risk Factors” and elsewhere in the Company’s Quarterly Report on Form 10-Q filed with
the SEC on November 5, 2020, and in the Company’s subsequent SEC filings. These forward-looking statements speak only
as of the date of this Current Report on Form 8-K, and the Company undertakes no obligation to update these forward-looking
statements.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Ironwood Pharmaceuticals, Inc.
|
|
|
|
|
|
|
Dated: February 8, 2021
|
By:
|
/s/ Gina Consylman
|
|
|
Name:
|
Gina Consylman
|
|
|
Title:
|
Senior Vice President, Chief Financial Officer
|
Ironwood Pharmaceuticals (NASDAQ:IRWD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ironwood Pharmaceuticals (NASDAQ:IRWD)
Historical Stock Chart
From Jul 2023 to Jul 2024